What was the TLR rate for DCB in the AGENT IDE trial?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Practice for Clinical Training 1 (CT1) Day 4 Exam. Enhance your skills with a range of questions designed to test your clinical knowledge. Each question features detailed explanations to help you succeed.

Multiple Choice

What was the TLR rate for DCB in the AGENT IDE trial?

Explanation:
In the context of the AGENT IDE trial, the target lesion revascularization (TLR) rate for drug-coated balloons (DCB) was reported to be 12.4%. This figure reflects the number of patients who required repeat procedures to address issues with the target lesions after being treated with DCB, indicating the efficacy of this treatment method in reducing the need for additional interventions. The outcome of 12.4% suggests a relatively favorable result for DCB use, demonstrating that these devices can effectively treat occlusions while minimizing the likelihood of subsequent procedures. This finding is significant because it helps clinicians assess the performance of DCB in comparison to other treatment modalities, especially in terms of long-term outcomes and patient management. The other figures, while they represent various clinical outcomes or rates associated with other studies or treatment options, do not align with the specific findings of the AGENT IDE trial regarding TLR rates for DCB.

In the context of the AGENT IDE trial, the target lesion revascularization (TLR) rate for drug-coated balloons (DCB) was reported to be 12.4%. This figure reflects the number of patients who required repeat procedures to address issues with the target lesions after being treated with DCB, indicating the efficacy of this treatment method in reducing the need for additional interventions.

The outcome of 12.4% suggests a relatively favorable result for DCB use, demonstrating that these devices can effectively treat occlusions while minimizing the likelihood of subsequent procedures. This finding is significant because it helps clinicians assess the performance of DCB in comparison to other treatment modalities, especially in terms of long-term outcomes and patient management.

The other figures, while they represent various clinical outcomes or rates associated with other studies or treatment options, do not align with the specific findings of the AGENT IDE trial regarding TLR rates for DCB.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy